13896-06-5

Basic information

• Product Name: (4S)-4-Ethyl-2-oxazolidinone
• Synonyms: (4S)-4-Ethyl-2-oxazolidinone
• CAS NO: 13896-06-5
• Molecular Formula: C₅H₉NO₂
• Molecular Weight: 115.13046
• Mol File: 13896-06-5.mol
• Article Data: 33

Chemical Properties

• Boiling Point: 298.9°Cat760mmHg
• Flash Point: 134.5°C
• Appearance: /
• Density: 1.047g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.428
• CAS DataBase Reference: (4S)-4-Ethyl-2-oxazolidinone(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-4-Ethyl-2-oxazolidinone(13896-06-5)
• EPA Substance Registry System: (4S)-4-Ethyl-2-oxazolidinone(13896-06-5)

Safety Data

• Hazardous Substances Data: 13896-06-5(Hazardous Substances Data)

Usage

General Description

(4S)-4-Ethyl-2-oxazolidinone, also known as 4-ethyl-2-oxazolidinone or 4S-ethyl-2-oxazolidin-2-one, is a chemical compound with the molecular formula C5H9NO2. It is a cyclic organic compound with a five-membered ring containing an oxygen and nitrogen atom. (4S)-4-Ethyl-2-oxazolidinone is used as a versatile chiral building block in organic synthesis, particularly in the pharmaceutical industry for the preparation of chiral drugs and intermediates. It is also used as a solvent and reagent in various chemical reactions, including asymmetric synthesis. Additionally, it has been reported to have antimicrobial and antifungal properties, making it potentially useful in the development of new antimicrobial agents. Overall, (4S)-4-ethyl-2-oxazolidinone has various important applications in organic chemistry and pharmaceutical research.

InChI:InChI=1/C5H9NO2/c1-2-4-3-8-5(7)6-4/h4H,2-3H2,1H3,(H,6,7)/t4-/m0/s1

Upstream product

• 96-20-8 2-aminobutanol 
• 1659-31-0 2,2'-dipyridyl carbonate 
• 592-35-8 butyl carbamate 
• 71005-75-9 4-ethyloxazol-2(3H)-one 
• 5856-62-2 (S)-2-aminobutan-1-ol 
• 124-38-9 carbon dioxide 
• 105-58-8 Diethyl carbonate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 530-62-1 1,1'-carbonyldiimidazole 
• 110418-29-6 (S)-(-)-2--1-butanol 
• 468756-92-5 (4S,2'S,3'R)-N-(3-acetoxy-2-methylbutanoyl)-4-ethyl-2-oxazolidinone 
• 57-13-6 urea 
• 2549-67-9 2-ethylaziridine 
• 13973-23-4 2--1-butanol 

Downstream Products

• 572923-13-8 4-(4-ethyl-2-oxo-oxazolidin-3-yl)-benzoic acid methyl ester 
• 6744-64-5 N,N'-dibenzhydryl-urea 
• 101785-47-1 N-benzhydryl-N'-(1-hydroxymethyl-propyl)-urea 
• 1466-67-7 1,3-dibenzylurea 
• 100317-12-2 N-benzyl-N'-(1-hydroxymethyl-propyl)-urea 
• 5467-84-5 1,3-diphenethylurea 
• 1269644-84-9 (S)-3-(3-(4-(1H-1,2,4-triazol-3-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-ethyloxazolidin-2-one 
• 1269648-79-4 (S)-4-ethyl-3-(3-(4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazol-3-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)oxazolidin-2-one 
• 909566-58-1 1-((S)-1-hydroxybutane-2-yl)pyrrolidin-2-one 
• 572922-98-6 4-(4-ethyl-2-oxo-oxazolidin-3-yl)-benzaldehyde 
• 572923-16-1 4-(4-ethyl-2-oxo-oxazolidin-3-yl)-N-propyl-benzamide 
• 572923-01-4 4-ethyl-3-(3-methoxy-phenyl)-oxazolidin-2-one 
• 572923-06-9 4-ethyl-3-(p-tolyl)-oxazolidin-2-one 

Relevant articles and documents

Synchronized stereocontrol of planar chirality by crystallization-induced asymmetric transformation

Synchronized stereocontrol of two planar-chiral units was accomplished by using crystallization-induced asymmetric transformation (CIAT) of cyclophane-type bridged bisnicotinate derivatives 5b and 7. After screening various linkers, (S)-2-amino-1-butanol

-

-

Preparation method of ethambutol

The invention relates to a preparation method of an antituberculosis drug ethambutol. The preparation method specifically comprises the following steps: a, reacting 2-amino-1 butanol with carbonic ester to generate a compound 2, b, reacting the compound 2 with dihalogenated ethane to generate a compound 3, and c, hydrolyzing the compound 3 to generate ethambutol. According to the preparation method of the ethambutol, the adopted raw materials are low in price and easy to obtain, and the method has the advantages of short synthetic route, novel route, high yield and no dangerous process.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.